Viridian Therapeutics
VRDN
235 hedge funds and large institutions have $2.83B invested in Viridian Therapeutics in 2026 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 84 increasing their positions, 63 reducing their positions, and 23 closing their positions.
91% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 23
33% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 63
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
13% more capital inflows, than outflows
Capital inflows: $402M | Capital outflows: $358M
8% more funds holding
Funds holding: 217 → 235 (+18)
11.94% less ownership
Funds ownership: 133.11% → 121.18% (-12%)
72% less call options, than puts
Call options by funds: $3.3M | Put options by funds: $11.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RTW Investments
New York
|
+$105M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$48.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$39.3M |
| 4 |
Paradigm Biocapital Advisors
New York
|
+$32.7M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$19.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$43.8M |
| 2 |
Deep Track Capital
Greenwich,
Connecticut
|
-$40.2M |
| 3 |
Fisher Asset Management
Camas,
Washington
|
-$32.2M |
| 4 |
State Street
Boston,
Massachusetts
|
-$26.7M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$24.3M |
VRDN Hedge Fund Activity: Q3 2026 in Review
235 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q3 2026, worth a combined $2.83B — up 13% from $2.5B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new VRDN positions and 23 closed out — a net gain of 21 holders — while 84 added to existing stakes and 63 trimmed.
The largest buyer was RTW Investments, opening a new position worth an estimated $105M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $43.8M sold.
- 235 institutional investors held Viridian Therapeutics (VRDN) as of Q3 2026, up from 217 in Q2 2026.
- Funds reported $2.83B of Viridian Therapeutics stock for Q3 2026, up 13% quarter-over-quarter.
- 44 funds opened new Viridian Therapeutics positions in Q3 2026 and 23 closed out, a net change of +21 holders.
- The largest Viridian Therapeutics buyer in Q3 2026 was RTW Investments, an estimated $105M added.
- The largest Viridian Therapeutics seller in Q3 2026 was Baker Bros. Advisors, an estimated $43.8M sold.
Based on aggregated 13F filings for Q3 2026.